MCPIP1 Elicits a Therapeutic Effect on Cervical Cancer by Facilitating XIAP mRNA Decay via Its Endoribonuclease Activity
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms251910285 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Junyun Luo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology of College of Biology, Hunan University, Changsha 4…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Ribonucleases, X-Linked Inhibitor of Apoptosis Protein, RNA Stability. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Hunan, Natural Science Foundation of Chongqing, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cervical cancer is the fourth most common malignancy in women globally. Chemotherapies, targeted therapies, and immunotherapies in the treatment of cervical cancer are usually accompanied by effective and adverse effects. Therefore, finding other efficient and accurate molecular targets remains essential to improve the treatment benefits of cervical cancer patients. MCPIP1 (monocyte chemoattractant protein-induced protein 1) is a kind of endonuclease with a CCCH zinc finger domain and a PilT-N-terminal (PIN) domain, and its function in cervical cancer is unknown. We found that MCPIP1 inhibits cell proliferation and promotes cell apoptosis of cervical cancer. Additionally, MCPIP1 suppresses mRNA and protein expression of the apoptotic inhibitor XIAP by decreasing its mRNA stability. Mechanically, MCPIP1 binds to the XIAP mRNA via its CCCH zinc finger domain and degrades the XIAP mRNA via the endonuclease activity coming from its PIN domain. Our study clarifies that MCPIP1 promotes cervical cancer cell apoptosis by suppressing the expression of XIAP, thereby impeding cervical cancer progression. Moreover, targeted delivery of MCPIP1 with engineered Salmonella typhimurium leads to tumor growth retardation in the HeLa xenograft tumor model in mice. Therefore, our study may provide a theoretical basis for formulating clinical treatment strategies for cervical cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hunan Provincial Key Laboratory of Medical Virology, Institute of Pathogen Biology and Immunology of College of Biology, Hunan University, Changsha 410082, China.
- School of Biomedical Sciences, Hunan University, Changsha 410082, China.
- State Key Laboratory of Chemical Oncogenomics, Tsinghua Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
ORCID-Profile: Zhaoyong Li
Förderung
- Natural Science Foundation of Hunan
- Natural Science Foundation of Chongqing
- National Natural Science Foundation of China
Zitieren
APA
Luo, J., He, L., Guo, Y., Wang, J., Liu, H., & Li, Z. (2024). MCPIP1 Elicits a Therapeutic Effect on Cervical Cancer by Facilitating XIAP mRNA Decay via Its Endoribonuclease Activity. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms251910285
Vancouver
Luo J, He L, Guo Y, Wang J, Liu H, Li Z. MCPIP1 Elicits a Therapeutic Effect on Cervical Cancer by Facilitating XIAP mRNA Decay via Its Endoribonuclease Activity. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms251910285
BibTeX
@article{Luo2024,
author = {Luo, Junyun and He, Ling and Guo, Yanxia and Wang, Junzhi and Liu, Hui and Li, Zhaoyong},
title = {MCPIP1 Elicits a Therapeutic Effect on Cervical Cancer by Facilitating XIAP mRNA Decay via Its Endoribonuclease Activity},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms251910285}
}
EUVIMED